Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 1998

View Archived Issues

Antiallergic efficacy of dual-action compound demonstrated in preclinical models

Company Profile: Athersys

Novel AIDS therapy shows promise

Atrix receives CE mark approval for Atrisorb; ISO 9001 certification granted

Nastech licenses nasal scopolamine to Schwarz

Eisai in-licenses antiobesity drug for Japanese market

Photofrin enters phase III testing for new indication

New use approved for Lescol

U.S. marketing application submitted for AD-32

PDE IV/TNF production inhibitors claimed by Schering AG for MS

Novartis discloses HIV protease inhibitors with excellent pharmacodynamic profile

Vertex describes new IMPDH inhibitors

Serotonergic agents prepared at Merck KGaA as potential antidepressants/anxiolytics

Merck & Co. describes new thrombin inhibitors

Novel ET antagonists claimed by BASF

Agents with affinity for 5-HT2 receptors under development at Janssen

Takeda obtains remaining HMR stake in French joint venture

Abgenix and Pfizer collaborate on XenoMouse antibodies

AHC-52, a new dihydropyridine with cardioprotective effects

Pharmacological profile of parenteral ET antagonist for SAH described by Roche

Preclinical and preliminary clinical results reported for CS-834

IC-351 advances to phase II for MED

DuPont Merck, Signal collaborate on HCV and HIV research

Abbott in-licenses lipid-lowering drug from Fournier

Korean researchers discover new PLC and PI turnover inhibitor from fungal strain

Indian researchers describe new anticancer agent

Carbapenems with enhanced antipseudomonal activity and stability

Genzyme Transgenics breakthrough could lead to potential malaria vaccine

IMPDH inhibitor VX-497 advances to clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...